News

Nuvation Bio Inc (NYSE: NUVB) stock fell 13% after receiving FDA approval for its lung cancer drug IBTROZI, compared to a 1% decline in the XBI biotech index.
The BIO-LIBRA study evaluated contemporary outcomes with an implantable cardioverter defibrillator vs. cardiac resynchronization therapy in patients with nonischemic cardiomyopathy, with an ...
Shawn Levy’s new Clint Eastwood biography, 'Clint: The Man and The Movies,' includes details about what the actor-filmmaker called 'addictive' extramarital affairs.
The St. Louis Blues signed center Pius Suter to a two-year, $8.25 million contract on Wednesday, league sources told The Athletic’s Chris Johnston. The deal will be worth $4.125 million against ...
The post Grading Pius Suter’s 2-year contract with Blues appeared first on ClutchPoints. There were few fireworks on July 1 when 2025 NHL Free Agency began. In fact, many of the more notable ...
Just a few days after Khaman Maluach found his new NBA home, NBA fans noticed something interesting about the rookie big man’s Instagram bio. Philadelphia 76ers ...
Federal judge releases Kseniia Petrova, a Russian-born cancer researcher accused of smuggling frog embryo samples, while limiting her travel and maintaining custody of her passport.
Multiple reports had the Blues signing Pius Suter to a two-year contract worth $8.25 million ($4.125 million average annual value). The team confirmed the signing.
According to insider Frank Seravalli, Pius Suter is on his way to the St. Louis Blues. The contract is reportedly a 2 year deal worth $4 million annually for a total of $8 million.
NHL insider Rick Dhaliwal expressed frustration that the Vancouver Canucks "never showed the love" to forward Pius Suter before he left the team in free agency this week.
Pius Suter, who is coming off the strongest season of his career, is headed to St. Louis on a two-year deal worth $4.125 annually.
IISR develops eco-friendly bio-pesticide to combat cardamom thrips, reducing crop losses and promoting sustainable farming practices.